Give the Federal Trade Commission points for persistence.
For the past 12 years, the agency has been pushing to end what are known in the context of pharmaceutical patent litigation as reverse payment settlements, or pay-for-delay deals. And despite repeated setbacks, the FTC’s objections to these deals—under which brand-name drug companies offer generic rivals cash payments and other forms of compensation to drop patent challenges and delay entry to the market—appear to only have gotten stronger with time.
